<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140930</url>
  </required_header>
  <id_info>
    <org_study_id>NL59530.068.16</org_study_id>
    <nct_id>NCT03140930</nct_id>
  </id_info>
  <brief_title>The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake</brief_title>
  <official_title>The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The appearance of tastants in the small intestine can result in the activation of
      a negative feedback mechanism from different parts of the intestine to the stomach, the small
      intestine and to the central nervous system. These processes inhibit food processing,
      appetite sensations and food intake, and furthermore they increase feelings of satiety and
      satiation. The effects of intraduodenal and/or intraileal infusion of a combination of
      tastants (sweet (rebaudioside A), bitter (quinine) en umami (monosodium glutamate(MSG))) and
      placebo on ad libitum food intake, satiation and gastrointestinal symptoms will be
      investigated.

      Objective: To investigate the effect of intraduodenal, intraileal and combined infusion of a
      combination of tastants versus infusion of placebo on food intake.

      Secondary objectives:

        1. To compare the effect of intraduodenal versus intraileal versus combined intraduodenal
           and intraileal delivery of a combination of tastants on satiation.

        2. To assess the effect of intraduodenal and/or intraileal delivery of a combination of
           tastants on gastrointestinal symptoms/complaints.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum meal intake</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in ad libitum meal intake (as measured during ad libitum pasta meal) at end of the test day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiation</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in satiation (as measured by VAS) per time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI-symptoms</measure>
    <time_frame>5 weeks</time_frame>
    <description>Difference in gastro-intestinal symptoms (as measured by VAS) per time point.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Duodenal tastants, ileal placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duodenal placebo, ileal tastants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duodenal tastants, ileal tastants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duodenal placebo, ileal placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tastants duodenal</intervention_name>
    <description>Duodenal infusion of combination of tastants (sweet, bitter and umami)</description>
    <arm_group_label>Duodenal tastants, ileal placebo</arm_group_label>
    <arm_group_label>Duodenal tastants, ileal tastants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tastants ileal</intervention_name>
    <description>Ileal infusion of combination of tastants (sweet, bitter and umami)</description>
    <arm_group_label>Duodenal placebo, ileal tastants</arm_group_label>
    <arm_group_label>Duodenal tastants, ileal tastants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo duodenal</intervention_name>
    <description>Duodenal infusion of placebo (tap water)</description>
    <arm_group_label>Duodenal placebo, ileal tastants</arm_group_label>
    <arm_group_label>Duodenal placebo, ileal placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo ileal</intervention_name>
    <description>Ileal infusion of placebo (tap water)</description>
    <arm_group_label>Duodenal tastants, ileal placebo</arm_group_label>
    <arm_group_label>Duodenal placebo, ileal placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Based on medical history and previous examination, no gastrointestinal complaints can
             be defined.

          -  Age between 18 and 65 years. This study will include healthy adult subjects (male and
             female). Women must be taking contraceptives.

          -  BMI between 18 and 25 kg/m2)

          -  Weight stable over at least the last 6 months

        Exclusion Criteria:

          -  History of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic,
             hematological/immunologic, HEENT (head, ears, eyes, nose, throat),
             dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurological/psychiatric diseases, allergy, major surgery and/or laboratory
             assessments which might limit participation in or completion of the study protocol.
             The severity of the disease (major interference with the execution of the experiment
             or potential influence on the study outcomes) will be decided by the principal
             investigator.

          -  Use of medication, including vitamin supplementation, except oral contraceptives,
             within 14 days prior to testing

          -  Administration of investigational drugs or participation in any scientific
             intervention study which may interfere with this study (to be decided by the principle
             investigator), in the 180 days prior to the study

          -  Major abdominal surgery interfering with gastrointestinal function (uncomplicated
             appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon
             judgement of the principle investigator)

          -  Dieting (medically prescribed, vegetarian, diabetic, microbiological, biological
             dynamic)

          -  Pregnancy, lactation

          -  Excessive alcohol consumption (&gt;20 alcoholic consumptions per week)

          -  Smoking

          -  Weight &lt;60kg

          -  Non-tasters of sweet, bitter or umami

          -  Evidence of MSG-hypersensitivity or Chinese restaurant syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad AM Masclee, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Klaassen, MD</last_name>
    <phone>+3143-3882134</phone>
    <email>t.klaassen@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annick E Alleleyn, MD</last_name>
    <phone>+3143-3884190</phone>
    <email>a.alleleyn@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Klaassen, MD</last_name>
      <phone>+3143-3882134</phone>
      <email>t.klaassen@maastrichtuniversity.nl</email>
    </contact>
    <contact_backup>
      <last_name>Annick E Alleleyn, MD</last_name>
      <phone>+3143-3884190</phone>
      <email>a.alleleyn@maastrichtuniversity.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ad AM Masclee, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Tim Klaassen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

